Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

AVRO

AvroBio Inc

May 16 • 02:17PM ET

1.37

Dollar change -0.00
Percentage change -0.36	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF

Scroll to Statements

Index	-	P/E	1.98	EPS (ttm)	0.69	Insider Own	12.52%	Shs Outstand	44.65M	Perf Week	9.20%
Market Cap	61.27M	Forward P/E	-	EPS next Y	-	Insider Trans	15.80%	Shs Float	39.27M	Perf Month	11.89%
Income	30.31M	PEG	-	EPS next Q	-	Inst Own	49.76%	Short Float	0.42%	Perf Quarter	4.20%
Sales	0.00M	P/S	-	EPS this Y	-3950.00%	Inst Trans	-6.02%	Short Ratio	0.74	Perf Half Y	3.41%
Book/sh	1.98	P/B	0.69	EPS next Y	-	ROA	34.57%	Short Interest	0.16M	Perf Year	113.62%
Cash/sh	2.02	P/C	0.68	EPS next 5Y	-	ROE	42.73%	52W Range	0.57 - 1.70	Perf YTD	0.37%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	34.11%	52W High	-19.71%	Beta	1.21
Dividend TTM	-	Quick Ratio	26.17	Sales past 5Y	0.00%	Gross Margin	-	52W Low	139.47%	ATR (14)	0.06
Dividend Ex-Date	-	Current Ratio	26.17	EPS Y/Y TTM	130.18%	Oper. Margin	0.00%	RSI (14)	63.90	Volatility	7.00% 4.28%
Employees	13	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	2.00
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	73.18%	Payout	0.00%	Rel Volume	0.81	Prev Close	1.37
Sales Surprise	-	EPS Surprise	0.00%	Sales Q/Q	-	Earnings	-	Avg Volume	221.56K	Price	1.37
SMA20	10.41%	SMA50	8.34%	SMA200	-1.82%	Trades		Volume	134,589	Change	-0.36%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-18-23	Downgrade	Mizuho	Buy → Neutral
Jan-05-22	Downgrade	BTIG Research	Buy → Neutral
Nov-19-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$24 → $7
Jun-15-21	Initiated	BTIG Research	Buy	$23
May-27-21	Initiated	Needham	Buy	$28
Mar-09-21	Initiated	Barclays	Overweight	$23
Mar-02-21	Initiated	Stifel	Hold	$14
Nov-11-20	Initiated	Berenberg	Buy
Mar-31-20	Downgrade	H.C. Wainwright	Buy → Neutral	$13
Jun-27-19	Initiated	Mizuho	Buy	$28
Apr-05-19	Initiated	Janney	Buy
Oct-10-18	Initiated	Guggenheim	Buy
Oct-02-18	Reiterated	H.C. Wainwright	Buy	$47 → $40
Sep-17-18	Initiated	H.C. Wainwright	Buy	$47
Jul-16-18	Initiated	Wells Fargo	Outperform	$40
Jul-16-18	Initiated	Wedbush	Outperform	$38
Jul-16-18	Initiated	Morgan Stanley	Overweight	$37

Show Previous Ratings

May-15-24 11:27AM	Avrobio Insider Bought Shares Worth $971,493, According to a Recent SEC Filing (MT Newswires) +6.20%
May-13-24 09:53AM	AVRO Stock Earnings: Avrobio Beats EPS for Q1 2024 (InvestorPlace) +9.76%
Feb-27-24 10:50AM	Kuehn Law Encourages CHRD, AVRO, KAMN, and CTLT Investors to Contact Law Firm (PR Newswire)
Feb-01-24 02:25PM	Kuehn Law Encourages ICVX, CSTR, AVRO, and CALB Investors to Contact Law Firm (PR Newswire)
Jan-31-24 10:40AM	SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates TAST, AVRO, CALB (GlobeNewswire) +9.57%
06:42AM	Loading…
06:42AM	Avrobios road ends in reverse merger with Tim Springer-backed startup (BioPharma Dive)
Jan-30-24 02:52PM	Avrobio's corporate tremor attracts Tectonic for reverse merger (FierceBiotech.com) -16.06%
02:38PM	SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates AVRO, CALB, BCAL (PR Newswire)
08:00AM	AVROBIO and Tectonic Therapeutic Announce Merger (Business Wire)
Nov-08-23 09:40AM	Is AVROBIO (AVRO) Stock Outpacing Its Medical Peers This Year? (Zacks)
Oct-23-23 09:40AM	Is AVROBIO (AVRO) Outperforming Other Medical Stocks This Year? (Zacks)
Oct-06-23 09:40AM	Has AVROBIO (AVRO) Outpaced Other Medical Stocks This Year? (Zacks)
Jul-13-23 07:08AM	AVROBIO (AVRO) to Explore Strategic Options, Stock Rises 46% (Zacks)
Jul-12-23 07:00AM	AVROBIO to Explore Strategic Alternatives (Business Wire) +45.96%
Jun-12-23 07:00AM	AVROBIO Completes Sale of Cystinosis Gene Therapy Program for $87.5 Million (Business Wire)
07:00AM	Loading…
May-22-23 07:00AM	AVROBIO Announces Agreement to Sell Cystinosis Gene Therapy Program for $87.5 Million (Business Wire) +69.01%
May-18-23 02:53PM	Avrobio Touts Positive Data Gene Therapy Trial For Cystinosis, Showing Treatment Durability Of Up To 36 Months (Benzinga) +45.33%
07:00AM	AVROBIO Announces Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis at the ASGCT 26th Annual Meeting (Business Wire)
May-11-23 07:00AM	AVROBIO Reports First Quarter 2023 Financial Results and Provides Business Update (Business Wire)
May-01-23 07:30AM	AVROBIO Announces Leadership Transition (Business Wire) -15.99%
Mar-23-23 07:00AM	AVROBIO Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update (Business Wire) -27.64%
Mar-03-23 07:00AM	AVROBIO to Participate in Cowens 43rd Annual Health Care Conference (Business Wire)
Feb-09-23 07:00AM	AVROBIO to Present Clinical and Preclinical Data from Lysosomal Disorder Gene Therapy Pipeline at WORLDSymposium 2023 (Business Wire) +7.69%
Jan-05-23 07:00AM	AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-07-22 07:30AM	AVROBIO Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for its Gaucher Disease Gene Therapy (Business Wire) -6.96%
Nov-17-22 07:00AM	AVROBIO to Share Comprehensive Gaucher Disease Program Update (Business Wire) +5.40%
Nov-08-22 07:00AM	AVROBIO Reports Third Quarter 2022 Financial Results and Provides Business Update (Business Wire)
Nov-07-22 07:00AM	AVROBIO to Participate in the Sixth Annual Barclays Gene Editing/Therapy Summit (Business Wire)
Nov-03-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-27-22 07:00AM	AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for First-in-Class Gene Therapy for Gaucher Disease (Business Wire)
07:00AM	Loading…
Oct-25-22 07:00AM	AVROBIO Announces Completion of Patient Dosing in First Gene Therapy Clinical Trial for Cystinosis (Business Wire)
Oct-18-22 07:00AM	AVROBIO Granted ILAP Designation from U.K. MHRA for First-in-Class Gene Therapy for Gaucher Disease (Business Wire) +12.37%
Oct-11-22 07:00AM	AVROBIO Reports Favorable Data on Use of Combined State-of-the-art In Vitro Cell-based Assays to Identify Potential Genotoxicity Risk of Integrating Vectors During Preclinical Development (Business Wire)
Oct-06-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-27-22 07:00AM	AVROBIO to Present New Preclinical Data on Vector Safety at ESGCT Annual Congress (Business Wire) -10.23%
Sep-20-22 07:00AM	AVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration (FDA) for First Gene Therapy in Development for Cystinosis (Business Wire)
Sep-14-22 07:28AM	AVROBIO Announces Neuronopathic Mucopolysaccharidosis Type II (nMPS-II) or Hunter Syndrome Clinical Trial Application (CTA) Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy Trial (Business Wire)
Sep-08-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-31-22 07:00AM	AVROBIO to Participate in Four Upcoming Investor Conferences in September (Business Wire)
Aug-09-22 07:00AM	AVROBIO Reports Second Quarter 2022 Financial Results and Provides Business Update (Business Wire)
Aug-04-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-01-22 07:00AM	AVROBIO to Participate in Two Upcoming Investor Conferences in August (Business Wire)
Jul-13-22 07:00AM	AVROBIO Receives Orphan Drug Designation from the U.S. Food and Drug Administration for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome (Business Wire)
Jul-06-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.47%
May-18-22 03:12PM	AVROBIO (AVRO) Stock Up on Upbeat Data From Cystinosis Study (Zacks) -8.57%
12:41PM	Avrobio's Pompe Disease Gene Therapy Shows Efficacy, Safety In Preclinical Study (Benzinga)
07:00AM	AVROBIO Announces Preclinical Gene Therapy Data for Pompe Disease at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting (Business Wire)
May-17-22 12:15PM	AVROBIO Shares Jumps On Encouraging Data From Early-Stage Gene Therapy Study (Benzinga)
07:00AM	AVROBIO Reports Positive Data From Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive Measures (Business Wire)
May-16-22 07:00AM	AVROBIO to Present at the H.C. Wainwright Global Investment Conference (Business Wire)
May-10-22 07:00AM	AVROBIO Reports First Quarter 2022 Financial Results and Provides Business Update (Business Wire)
May-06-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-03-22 07:00AM	AVROBIO to Present New Clinical and Preclinical Data at the ASGCT 25th Annual Meeting (Business Wire)
Apr-06-22 12:36PM	bluebird (BLUE) Undertakes Restructuring Moves to Curb Cash Burn (Zacks)
07:00AM	AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-05-22 12:54PM	Corcept (CORT) Completes Enrolment in Mid-Stage Weight Gain Study (Zacks)
07:00AM	AVROBIO to Present at the 21st Annual Needham Virtual Healthcare Conference (Business Wire)
Mar-17-22 07:00AM	AVROBIO Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update (Business Wire) +8.33%
Mar-01-22 07:00AM	AVROBIO to Present at Two Upcoming Investor Conferences in March (Business Wire)
Feb-21-22 12:14PM	2 Net Current Asset Value Stocks to Consider (GuruFocus.com)
Feb-09-22 12:55PM	After Fabry Trial Setback, Avrobio Hopes Rebound With Lysosomal Storage Disorder Data (Benzinga) -6.25%
07:00AM	AVROBIO Reports Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis (Business Wire)
Feb-04-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-03-22 10:00AM	Here's Why AVROBIO, Inc. (AVRO) is Poised for a Turnaround After Losing 19.7% in 4 Weeks (Zacks)
Feb-01-22 07:00AM	AVROBIO Announces the Appointment of Sean OBryan as Chief Regulatory Officer (Business Wire)
Jan-28-22 07:00AM	AVROBIO to Present at Cowens 2nd Annual Genetic Medicines Summit (Business Wire) +6.32%
Jan-27-22 07:00AM	AVROBIO to Present New Data from Phase 1/2 Clinical Trial in Cystinosis at WORLDSymposium 2022 (Business Wire) -5.43%
Jan-25-22 10:00AM	Bears are Losing Control Over AVROBIO, Inc. (AVRO), Here's Why It's a 'Buy' Now (Zacks)
Jan-07-22 10:00AM	Here's Why AVROBIO, Inc. (AVRO) is Poised for a Turnaround After Losing 44.1% in 4 Weeks (Zacks)
Jan-06-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-04-22 02:28PM	AvroBio shares plunge after company halts development of Fabry drug (American City Business Journals) -36.63%
09:07AM	Wedbush Says Avrobio Shares Still Undervalued Despite 33% Fall (Investing.com)
07:57AM	Why Avrobio's Shares Are Plunging Today (Benzinga)
07:00AM	AVROBIO Reprioritizes Pipeline Programs (Business Wire)
Dec-07-21 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.67%
Dec-04-21 06:25AM	Is AVROBIO (NASDAQ:AVRO) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Nov-24-21 07:00AM	AVROBIO Presents Clinician Experience with FAB-GT Clinical Trial and Updated Safety Data for Investigational Gene Therapies in Fabry Disease and Gaucher Disease Type 1 (Business Wire)
Nov-09-21 07:00AM	AVROBIO to Present at Two Upcoming Investor Conferences in November (Business Wire)
Nov-08-21 07:00AM	AVROBIO to Present Clinical and Preclinical Data at the 14th ICIEM Conference (Business Wire)
Nov-05-21 07:00AM	AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-04-21 07:00AM	AVROBIO Reports Third Quarter 2021 Financial Results and Provides Business Update (Business Wire)
Nov-03-21 07:00AM	AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome (Business Wire) +7.46%
Oct-26-21 07:00AM	AVROBIO Announces the Appointment of Essra Ridha, M.D., MRCP, FFPM, as Chief Medical Officer (Business Wire)
Oct-20-21 07:00AM	AVROBIO to Present at the Jefferies Virtual Gene Therapy/Editing Summit (Business Wire)
Oct-19-21 07:00AM	AVROBIO Reports New Interim Safety Data Across Investigational Gene Therapies for Fabry and Gaucher Disease Type 1 (Business Wire)
Oct-06-21 07:00AM	AVROBIO to Present New Clinical and Preclinical Data Across Multiple Programs at the ESGCT 28th Annual Congress (Business Wire) +5.06%
Oct-05-21 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-05-21 08:25AM	What Is The Ownership Structure Like For AVROBIO, Inc. (NASDAQ:AVRO)? (Simply Wall St.)
Sep-03-21 04:01PM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -7.66%
Sep-01-21 07:00AM	AVROBIO to Participate at Four Upcoming Investor Conferences (Business Wire)
Aug-05-21 07:00AM	AVROBIO Reports Second Quarter 2021 Financial Results and Provides Business Update (Business Wire) +7.59%
Aug-04-21 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-02-21 07:00AM	AVROBIO to Present at Two Upcoming Investor Conferences in August (Business Wire)
Jul-12-21 08:49AM	10 Best Stocks Under $10 to Buy Right Now (Insider Monkey) -6.41%
Jul-08-21 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-27-21 01:39PM	3 Strong Buy Stocks Under $10 That Can Rip Higher (TipRanks)
Jun-17-21 09:43AM	Gene Therapy Companies Undervalued, Positioned for Upside (TipRanks)
Jun-10-21 07:00AM	AVROBIO to Present at the JMP Securities Life Sciences Conference (Business Wire)
Jun-07-21 01:37PM	How a Cloud Is Lifting from Bluebird and Other Gene Therapy Stocks (Barrons.com) +7.00%
Jun-04-21 07:00AM	AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)

Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firm's clinical-stage programs include Fabry, Gaucher Type 1, Hunter syndrome Gaucher Type 3, Pompe, and Cystinosis. The company was founded by Geoff Mackay, Kim Warren, Christopher Mason, and Jeffrey Medin in 2015 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Leonard Braden Michael	10% Owner	May 14 '24	Buy	1.30	296,882	385,947	4,768,262	May 15 11:21 AM
Leonard Braden Michael	10% Owner	May 13 '24	Buy	1.25	469,753	585,546	4,471,380	May 15 11:21 AM
Golipour Azadeh	Chief Technology Officer	Feb 01 '24	Option Exercise	0.00	37,334	0	68,104	Feb 05 08:01 PM
Ostrowski Erik	Interim CEO, President and CFO	Feb 01 '24	Option Exercise	0.00	40,084	0	42,384	Feb 05 07:57 PM
Ridha Essra	Chief Medical Officer	Feb 01 '24	Option Exercise	0.00	32,834	0	32,834	Feb 05 07:59 PM
Avruch Steven	Chief Legal Officer	Feb 01 '24	Option Exercise	0.00	32,834	0	32,834	Feb 05 07:56 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AVRO

AvroBio Inc

Upgrade your FINVIZ experience